NASDAQ$PDSB
PDS Biotechnology Corporation · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
PDS Biotechnology reported a net loss for Q1 2024, increased R&D expenses, and provided updated data from the Phase 2 VERSATILE-002 clinical trial.
PDS Biotechnology reported a net loss of $10.6 million for the first quarter of 2024, compared to a net loss of $9.7 million for the same period in 2023. R&D expenses increased to $6.7 million, and the company announced positive, updated data from its Phase 2 VERSATILE-002 clinical trial.
- Reported a net loss of $10.6 million, or $0.30 per share.
- R&D expenses increased to $6.7 million due to higher clinical study and medical affairs costs.
- Announced updated results from the VERSATILE-002 Phase 2 trial, showing promising outcomes in HNSCC patients.
- Strengthened management with the addition of Stephan Toutain as Chief Operating Officer.
Headline financials
Revenue & EPS history
PDS Biotechnology · Revenue · Quarterly
$0
Forward guidance
PDS Biotechnology plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC).
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.0%
Avg return
30 days after
52%
22 / 42 earnings
Positive
+55.0%
Q3 2022
Best reaction
-27.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.1% | +5.7% | -3.8% | |
| Q3 2025 | -12.2% | -18.2% | +1.0% | |
| Q2 2025 | -4.9% | +0.8% | -5.7% | |
| Q1 2025 | +4.8% | +15.0% | +37.8% | |
| Q4 2024 | +0.8% | -12.9% | +0.8% | |
| Q3 2024 | -27.2% | -24.0% | -33.2% | |
| Q2 2024 | -1.0% | +6.6% | +0.0% | |
| Q1 2024 | -0.3% | -4.4% | -21.2% | |
| Q4 2023 | -11.6% | -10.3% | -27.0% | |
| Q3 2023 | +20.3% | +19.7% | +2.9% | |
| Q2 2023 | +21.2% | +17.1% | +13.2% | |
| Q1 2023 | +5.0% | +14.9% | -7.4% | |
| Q4 2022 | +2.2% | -4.7% | +1.0% | |
| Q3 2022 | +55.0% | +54.5% | +64.3% | |
| Q2 2022 | +0.2% | +1.9% | -21.7% | |
| Q1 2022 | -14.3% | +15.2% | -21.7% | |
| Q4 2021 | -1.1% | -1.0% | -12.1% | |
| Q3 2021 | -1.6% | +2.2% | -14.6% | |
| Q2 2021 | +0.6% | -6.5% | +44.5% | |
| Q1 2021 | +8.2% | +27.0% | +174.1% | |
| Q4 2020 | +1.9% | -5.3% | +2.3% | |
| Q3 2020 | -0.5% | -1.9% | +3.8% | |
| Q2 2020 | -5.1% | +0.7% | -26.5% | |
| Q1 2020 | -2.3% | -1.8% | +39.3% | |
| Q4 2019 | +2.3% | -7.9% | +29.6% | |
| Q3 2019 | +0.0% | -14.0% | -3.4% | |
| Q2 2019 | +1.1% | -0.5% | -15.2% | |
| Q1 2019 | +43.0% | +18.6% | +6.4% | |
| Q4 2018 | +3.8% | +2.6% | -1.7% | |
| Q3 2018 | -2.8% | -4.9% | -6.2% | |
| Q2 2018 | +1.3% | +0.0% | -4.3% | |
| Q1 2018 | -6.4% | -3.6% | -15.3% | |
| Q4 2017 | +1.5% | +9.4% | -92.2% | |
| Q3 2017 | +1.2% | -2.2% | -8.0% | |
| Q2 2017 | -1.2% | -3.1% | -2.0% | |
| Q1 2017 | +2.8% | +2.4% | +3.2% | |
| Q4 2016 | -9.5% | -8.8% | -7.1% | |
| Q3 2016 | -6.3% | -0.6% | +9.9% | |
| Q2 2016 | +1.9% | +0.1% | -4.6% | |
| Q1 2016 | -4.2% | — | — | |
| Q4 2015 | -14.2% | — | — | |
| Q3 2015 | +0.5% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro